ERBB2 and cancer: HER2 ADC cancer cell-killing activity was significantly reduced in the monocyte-depleted PBMC and cancer cell co-cultures (Supplementary Fig. 11b), supporting the above findings that the myeloid cells drive robust innate immune responses to eliminate cancer cells after STINGa ADC treatment.